17 completed, 6 unknown, 5 active not recruiting, 5 recruiting. 14 Phase 1, 12 Phase 2, 11 Not applicable, 2 Phase 3.
Follow Progressive Multiple Sclerosis: new trials by email Literature Review of Progressive Multiple Sclerosis trials Research Report on Progressive Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis CABA-201 - Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS) | Phase 1 / Phase 2 | Withdrawn | Cabaletta Bio | 2026-06-01 | 2026-06-25 | |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) RO7268489, Ocrelizumab, Placebo - Progressive Multiple Sclerosis | Phase 2 | Recruiting | Hoffmann-La Roche | 360 | 2026-03-10 | 2026-10-07 |
| Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients Virtual Reality, Standard care - Progressive Multiple Sclerosis, Depression | Not applicable | Recruiting | University of Michigan | 40 | 2025-12-15 | 2026-02-12 |
| Obe-cel in Refractory Progressive Forms of Multiple Sclerosis Obecabtagene autoleucel (obe-cel) - Progressive Multiple Sclerosis | Phase 1 | Recruiting | Autolus Limited | 24 | 2025-08-04 | 2026-10-16 |
| Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS) rapcabtagene autoleucel (YTB323) - Progressive Multiple Sclerosis | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 28 | 2024-12-12 | 2026-09-04 |
| ABA-101 in Participants With Progressive Multiple Sclerosis ABA-101 - Progressive Multiple Sclerosis | Phase 1 | Active not recruiting | Abata Therapeutics | 12 | 2024-09-11 | 2025-07-03 |
| Telerehabilitation in Progressive Multiple Sclerosis Digital Telerehabilitation (Euleria Home), Conventional therapy - Progressive Multiple Sclerosis | Not applicable | Unknown | Universita di Verona | 78 | 2024-06-30 | 2024-07-03 |
| A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis KYV-101 (Biological) - 0.33 ×10^8 cells, KYV-101 (Biological) - 1 ×10^8 cells, Chemotherapy: cyclophosphamide (CYC) - Progressive Multiple Sclerosis | Phase 1 | Active not recruiting | Bruce Cree | 10 | 2024-06-20 | 2026-08-10 |
| Study of Circadian Focused Light Therapy in Progressive Multiple Sclerosis Light therapy - Progressive Multiple Sclerosis | Phase 1 | Enrolling by invitation | University of Texas Southwestern Medical Center | 20 | 2024-04-18 | 2025-12-31 |
| Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis Transcranial static magnetic field stimulation (tSMS), Sham Transcranial static magnetic field stimulation (tSMS) - Progressive Multiple Sclerosis | Not applicable | Recruiting | Neuromed IRCCS | 40 | 2023-05-27 | 2024-10-16 |
| Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis Nicotinamid riboside, Placebo - Multiple Sclerosis, Progressive Multiple Sclerosis | Phase 2 | Recruiting | Haukeland University Hospital | 300 | 2023-05-03 | 2024-01-11 |
| Osmotin Plant Protein for Progressive Multiple Sclerosis Osmotin - Progressive Multiple Sclerosis | Not applicable | Unknown | Ospedale Policlinico San Martino | 50 | 2023-01-02 | 2023-07-10 |
| Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis Placebo, Masitinib (4.5) - Progressive Multiple Sclerosis | Phase 3 | Suspended | AB Science | 800 | 2022-06-28 | 2026-05-06 |
| Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis Eye tracking, Microperimetry, Optical coherence tomography (OCT) - Multiple Sclerosis, Clinically Isolated Syndrome | Enrolling by invitation | Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA | 120 | 2022-06-13 | 2025-05-16 | |
| Multiple Sclerosis Prediction and Monitoring of Progression Study Bytelfies kit - sensor dot - Progressive Multiple Sclerosis | Not applicable | Unknown | University Hospital, Ghent | 70 | 2022-03-01 | 2024-01-08 |
| Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis MSCs, Saline - Multiple Sclerosis, Progressive Multiple Sclerosis | Phase 1 / Phase 2 | Active not recruiting | Haukeland University Hospital | 18 | 2021-08-09 | 2026-03-12 |
| ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis Cladribine (MAVENCLAD®), Placebo - Advanced Multiple Sclerosis, Progressive Multiple Sclerosis | Phase 2 / Phase 3 | Active not recruiting | Queen Mary University of London | 204 | 2021-06-25 | 2026-09-08 |
| Effect of Variance on Error Correction During Coupling synchronisation abilities - Multiple Sclerosis, Progressive Multiple Sclerosis | Not applicable | Completed | Hasselt University | 13 | 2021-02-01 | 2025-02-27 |
| Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS) Adaptive Optics Ophthalmoscopy (AOO) - Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis | Not applicable | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 50 | 2020-12-01 | 2026-04-27 |
| Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis Blood withdrawal, MRI, Neurologic / neuropsychologic tests - Patients - Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis | Not applicable | Completed | University Hospital, Montpellier | 58 | 2019-12-09 | 2025-09-30 |
Showing 20 of 38. Sign in to see all of them.
Multiple Sclerosis, Chronic Progressive (38) · Multiple Sclerosis (18) · Multiple Sclerosis, Relapsing-Remitting (5) · Fatigue (2) · Autoimmune Diseases (1) · Charcot-Marie-Tooth disease, Type 1F (1) · Depression (1) · Eye Diseases (1) · Inflammation (1) · Nerve Degeneration (1) · Nervous System Diseases (1) · Neuromyelitis Optica (1) · Ocular Motility Disorders (1) · Optic Nerve Diseases (1) · Optic Neuritis (1)
Autoimmune Diseases of the Nervous System (38) · Chronic Disease (38) · Demyelinating Autoimmune Diseases, CNS (38) · Demyelinating Diseases (38) · Disease Attributes (38) · Immune System Diseases (38) · Pathologic Processes (38) · Pathological Conditions, Signs and Symptoms (38) · Autoimmune Diseases (37) · Nervous System Diseases (37) · Multiple Sclerosis (20) · Cranial Nerve Diseases (3) · Behavior (2) · Eye Diseases (2) · Signs and Symptoms (2)
Acyclovir (3) · Methylprednisolone (2) · Acetaminophen (1) · Acetylcysteine (1) · Biological Products (1) · Biotin (1) · Cladribine (1) · Eye-Tracking Technology (1) · Immunotherapy, Adoptive (1) · Loratadine (1) · Neuropsychological Tests (1) · Phototherapy (1) · Propensity Score (1) · Rituximab (1) · Sodium Chloride (1)
Genzyme, a Sanofi Company (3) · Haukeland University Hospital (2) · University Hospital, Montpellier (2) · AB Science (1) · Abata Therapeutics (1) · Anders Svenningsson (1) · Aristotle University Of Thessaloniki (1) · Autolus Limited (1) · Bruce Cree (1) · Cabaletta Bio (1) · Copenhagen University Hospital, Rigshospitalet (1) · Hasselt University (1) · Hoffmann-La Roche (1) · IRCCS San Raffaele (1) · Indiana University (1)
United States (9) · France (8) · Italy (7) · Spain (6) · Germany (5) · United Kingdom (5) · Australia (2) · Belgium (2) · Greece (2) · Norway (2) · Poland (2) · Sweden (2) · Brazil (1) · Canada (1) · China (1)
Anders Svenningsson, MD, PhD (1) · Bruce Cree, MD, PhD, MAS (1) · Celine Louapre, MD, PHD (1) · Christopher Elnan Kvistad, PhD (1) · Emmanuelle Waubant, MD, PhD (1) · Evan Campbell, MRes (1) · Gianvito Martino (1) · Guy Laureys, MD, PhD (1) · Hala Darwish, PhD (1) · Kjell-Morten Myhr (1) · Lousin Moumdjian, dr. (1) · Marialuisa Gandolfi (1)
PMID 39251561, PMID 12700753, PMID 16015332, PMID 19798728, PMID 20404843, PMID 22837038, PMID 26467901, PMID 27536708, PMID 30305449, PMID 33675156, PMID 36048877, PMID 36624312, PMID 39447576, PMID 39513023, PMID 40014609, PMID 41645795, PMID 41693928, PMID 41788164, PMID 42081777
2014 (2), 2016 (2), 2015 (1), 2018 (1), 2025 (1)